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Autosomal recessive genetic forms (DFNB) account for most cases of
profound congenital deafness. Adeno-associated virus (AAV)-based
gene therapy is a promising therapeutic option, but is limited by a
potentially short therapeutic window and the constrained packaging
capacity of the vector. We focus here on the otoferlin gene un-
derlying DFNB9, one of themost frequent genetic forms of congenital
deafness. We adopted a dual AAV approach using two different
recombinant vectors, one containing the 5′ and the other the 3′ por-
tions of otoferlin cDNA, which exceed the packaging capacity of the
AAV when combined. A single delivery of the vector pair into the
mature cochlea of Otof−/− mutant mice reconstituted the otoferlin
cDNA coding sequence through recombination of the 5′ and 3′
cDNAs, leading to the durable restoration of otoferlin expression in
transduced cells and a reversal of the deafness phenotype, raising
hopes for future gene therapy trials in DFNB9 patients.
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More than half the cases of nonsyndromic profound con-genital deafness have a genetic cause, and most (∼80%)
are autosomal recessive (DFNB) forms (1). Prosthetic cochlear
implants are currently used for rehabilitation (2), but hearing re-
covery is far from perfect, particularly for the perception of speech
in noisy environments or of music (2–4), highlighting a need for
more targeted curative treatments possibly including gene therapy.
Adeno-associated virus (AAV) recombinant vectors are a promis-
ing alternative to the more commonly used retrovirus and adeno-
virus vectors for therapeutic gene transfer in human diseases, and
they are currently being tested in phase I or phase II clinical trials
(5–8). Preclinical trials of local AAV-mediated gene therapy in
several mouse models of human forms of deafness have had mixed
success for preventing hearing impairment (9–19). In these studies,
the gene was delivered to the immature cochlea in newborn mice
[on postnatal day 1 or 2 (P1–P2)], well before hearing onset, which
occurs around P12 in this species (20). In humans, inner ear de-
velopment is completed in utero, with hearing onset at ∼20 wk of
gestation (21). However, hearing impairment in patients with
DFNB forms is typically diagnosed during the neonatal period.
Gene therapy approaches should therefore also be tested after the
period of hearing onset in animal models, to determine whether
they can reverse an existing deafness phenotype. We focused on
DFNB9 (MIM 601071), which accounts for 2–8% of all cases of
congenital genetic deafness. DFNB9 results from mutations of
OTOF encoding otoferlin, the major calcium sensor for synaptic
exocytosis in cochlear sensory cells [inner hair cells (IHCs)] (22–
27). Mutant mice lacking otoferlin (Otof−/− mice) are profoundly
deaf due to a failure of sound-evoked neurotransmitter release at
the IHC synapse, despite having a normal sensory epithelium
structure (28). They therefore constitute an appropriate model for
testing the efficacy of AAV-mediated gene therapy in the mature
cochlea. However, the limited DNA packaging capacity of AAVs
(about 4.7 kb) makes it difficult to use this technique for larger
genes, such as Otof (cDNA ∼6 kb). We overcame this size
limitation by adapting a previously reported dual AAV-vector
method for the delivery of large cDNAs (29). Our results
document both the preventive and curative efficacies of local
gene therapy in a mouse model of DFNB9, while expanding the
scope of potential AAV gene therapy applications for human
hereditary deafness forms.
Results and Discussion
An AAV2-based vector was engineered to express the green fluo-
rescent protein (GFP) gene under the control of a chimeric cyto-
megalovirus (CMV)–chicken β-actin promoter. This expression
cassette was packaged in the AAV2 quadY-F capsid wherein four
surface tyrosine (Y) residues of the AAV2 capsid have been
replaced by phenylalanine (F) residues, which was shown to increase
the efficiency of gene transfer in the retina (30). The recombinant
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virus was injected through the round window membrane into the left
cochlea of five wild-type mice on P2. GFP-immunostaining of the
sensory epithelium 2 wk after injection revealed the transduction of
various types of cells, including IHCs. The transduction rate for
IHCs was 78 ± 6% (mean ± SD), demonstrating the suitability of
this AAV serotype to deliver therapeutic genes to these cells (SI
Appendix, Fig. S1). The coding sequence of the murine otoferlin
cDNA was split into a 5′ fragment (Otof NT, nucleotides 1–2,448)
and a 3′ fragment (Otof CT, nucleotides 2,449–5,979), each of which
was inserted into an AAV vector carrying a recombinogenic bridging
sequence (29, 31). The AAV-Otof NT recombinant vector carries
the 5′ part of the cDNA followed by a splice donor site, and the
AAV-Otof CT recombinant vector carries a splice acceptor site
followed by the 3′ part of the cDNA (Materials and Methods and Fig.
1). Each of these recombinant vectors was packaged in the AAV2
quadY-F capsid. HEK293 cells were infected with AAV-Otof NT,
AAV-Otof CT, or both recombinant viruses, and immunostained for
otoferlin 48 h later. We used two different antibodies, directed
against the C-terminal part or the N-terminal part of the protein
(28) and obtained identical results. Otoferlin was detected only in
cells infected simultaneously with both viruses, thus indicating that
the two vectors were able to recombine and generate concatemers
via their inverted terminal repeats, with correct splicing of the
resulting transcript to produce the protein (Fig. 1).
A single unilateral injection of the AAV-Otof NT plus AAV-
Otof CT recombinant vector pair was administered to Otof−/− mice
through the round window membrane into the left cochlea, before
(on P10) or after hearing onset. Injections after hearing onset were
carried out at one of two different time points, P17 and P30, be-
cause the maturation of IHC ribbon synapses is still underway at
P17 (32, 33), whereas the cochlea is mature at P30 (20).
Eight weeks after the injection of the recombinant vector pair on
P10, the sensory epithelium of the treated cochleas of three Otof−/−
mice was microdissected and immunolabeled for otoferlin (with an
antibody directed against the C-terminal part of the protein) to esti-
mate the IHC transduction rate. The protein was detected in more
than 60% of the IHCs (64± 6%, mean ± SD, n= 3 cochleas), but not
in other cell types (Fig. 2A, Left). This result provides evidence that a
large cDNA can effectively be reconstituted in cochlear sensory cells
upon the local delivery of a recombinant AAV-vector pair in vivo, with
sustained, widespread production of the protein by a large proportion
of the cells. The accuracy of the pre-mRNA splicing process in
transduced cells was checked by RT-PCR and sequence analysis of a
large fragment of the otoferlin transcript encompassing the junction
between the Otof NT and Otof CT cDNAs (SI Appendix, Fig. S2).
Auditory brainstem response (ABR) recordings in the mice 4 wk after
the P10 injection demonstrated a substantial restoration of hearing
thresholds in response to click and tone-burst stimuli (8, 16, and 32
kHz) in all of the treated mice (n = 8), but no restoration in the
Otof−/− mice receiving either AAV-Otof NT or AAV-Otof CT alone
(n = 3 each), or in the absence of injection (n = 6) (Fig. 2 B and C).
The ABR thresholds for both click and tone-burst stimuli in the
treated mice were similar to those of control wild-type mice (n =
8; Mann–Whitney U test, P > 0.15 for all comparisons). We
evaluated the long-term efficacy of gene therapy by carrying out
ABR recordings in response to clicks at several postinjection time
points between 1 and 30 wk. From the fourth week onward, the
ABR thresholds of the treated mice did not differ significantly
from those of wild-type mice (Mann–Whitney U test, P > 0.05 for
comparisons at all stages) (Fig. 2B). However, the amplitudes of
ABR wave I, which reflects the electrical responses of primary
auditory neurons to the sound stimulus, were 39 ± 7% (mean ±
SD) of the mean value for wild-type mice (Mann–Whitney U test,
P = 0.002), whereas wave I latencies (1.15 ± 0.09 ms) were similar
to those in wild-type mice (1.27 ± 0.05 ms; Mann–Whitney U test,
P = 0.06) (Fig. 2C).
Thirty weeks after the injection, six of the eight mice receiving
injections on P10 still had hearing thresholds within 10 dB of those
of wild-type mice. Gene therapy before hearing onset therefore
prevents deafness in Otof−/− mice. We have previously shown that
about half of the IHC ribbons degenerate in Otof−/− mice (28). We
therefore analyzed the numbers of presynaptic ribbons (together
with postsynaptic glutamate receptors) in the transduced IHCs and
the nontransduced IHCs of treated Otof−/− cochleas 8 wk after the
injection on P10, by immunofluorescence and 3D confocal micros-
copy imaging (Fig. 2A, Right). The number of ribbons per IHC in
transduced cells (12.5 ± 1.8, mean ± SD, n = 48 cells from three
mice) was almost twice higher than in nontransduced cells (6.9 ± 1.3,
n = 48 cells from three mice; Mann–Whitney U test, P < 10−4), but
remained lower than in wild-type IHCs (16 ± 1.3, n = 48 cells from
three mice; Mann–Whitney U test, P < 10−4), potentially accounting
for the incomplete recovery of wave I amplitude on ABR recordings.
After injection of the recombinant vector pair into the cochleas of
P17 or P30 Otof−/−mice, otoferlin was detected in IHCs throughout
the treated cochlea, but not in IHCs of the contralateral cochlea (SI
Appendix, Fig. S3). IHC transduction rates were similar in the two
groups of mice (82 ± 9% and 85 ± 7%, for n = 5 and n = 3 cochleas
treated on P17 and P30, respectively), and higher than those in mice
receiving injections on P10 (Mann–WhitneyU test, P < 0.05 for both
comparisons) (Figs. 3A and 4A). ABR recordings 4 wk after in-
jection showed hearing recovery in all of the mice receiving injec-
tions on P17 (n = 5), with ABR thresholds in response to clicks or
Fig. 1. Expression of otoferlin in HEK293 cells following
dual AAV-vector delivery. (Left) Schematic representation of
the recombinant AAV-vector pair used in this study, and of
the recombination, transcription, splicing, and translation
processes producing the full-length protein otoferlin in
coinfected cells. The recombinant AAV-Otof NT and AAV-
Otof CT vectors contain the 5′ and 3′ parts of the otoferlin
cDNA, respectively. The recombinogenic bridging sequence
present in the two recombinant vectors is indicated by a
gray sphere. The redbars under theprotein diagramdenote
the twopeptides used toproduce theantibodies against the
N-terminal and C-terminal parts of otoferlin. Abbreviations:
C2, C2 domain; ITR, inverted terminal repeats; polyA, poly-
adenylation signal; SA, splice acceptor site; SD, splice
donor site; smCBA, cytomegalovirus immediate early/
chicken β-actin chimeric promoter; TM, transmembrane
domain. (Right) HEK293 cells were infected with AAV-
Otof NT alone (Upper), AAV-Otof CT alone (Middle), or
AAV-Otof NT and AAV-Otof CT together (Lower). They
were stained for otoferlin (green) with a polyclonal anti-
body directed against the C-terminal part of the protein
48 h later, and cell nuclei were labeled with DAPI (blue).
Only coinfected cells produce otoferlin. (Scale bars, 15 μm.)
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tone-burst stimuli remarkably similar to those in wild-type mice (n =
5; Mann–Whitney U test, P > 0.2 for all comparisons). Hearing
thresholds in response to clicks remained unchanged for 20 wk after
injection, demonstrating a sustained restoration of hearing in these
mice despite a mean ABR wave I amplitude about half that in wild-
type mice (47 ± 10%) (Fig. 3 B and C). Likewise, Otof−/− mice
receiving injections on P30 displayed a similar recovery of hearing as
early as 3 wk after the injection, with ABR thresholds in response to
clicks or tone-burst stimuli persisting at the wild-type level for 20 wk
postinjection (n = 3, Mann–Whitney U test, P > 0.1 for all com-
parisons), despite a mean ABR wave I amplitude about half (55 ±
10%) that in wild-type mice (Fig. 4 B and C). We analyzed the
numbers of presynaptic ribbons (together with postsynaptic gluta-
mate receptors) in the transduced IHCs and the nontransduced
IHCs of Otof−/− cochleas treated on P17 and on P30, by immuno-
fluorescence and 3D confocal microscopy imaging (Figs. 3A and 4A
and SI Appendix, Fig. S3). The numbers of ribbons per IHC in
transduced cells (10.0 ± 1.3, mean ± SD, n = 48 cells from three
mice treated on P17 and analyzed on P80, and 8.9 ± 2.3, n = 48
cells from three mice treated on P30 and analyzed on P40)
were higher than in nontransduced cells from the same co-
chleas (6.2 ± 1.3, n = 48 cells, and 5.8 ± 0.7, n = 48 cells, re-
spectively; Mann–Whitney U test, P < 10−4 for both
comparisons), but they were lower than in IHCs of 10-wk-old
wild-type mice (16 ± 1.3, n = 48 cells from three mice; Mann–
Whitney U test, P < 10−4 for both comparisons). As the number
of ribbons per IHC was already markedly reduced in untreated
Otof−/− mice analyzed on P17 (8.2 ± 1.0, n = 48 cells from three
mice), and remained unexpectedly stable in the nontransduced
IHCs of treated mice at later stages (see above the values for
P40, P70, and P80), we infer that gene therapy in the IHCs of
Otof−/− mice increased the number of ribbons by promoting their
production rather than preventing their degeneration.
Sustained transgene expression with AAVs has been achieved in
various animal models, and the excellent safety profile of these vec-
tors has been demonstrated in many ongoing clinical trials. As a re-
sult, AAVs are now the principal gene delivery system used in gene
therapy for genetic disorders (34–36). We report here, in the DFNB9
Fig. 2. Dual AAV-mediated gene therapy in P10
Otof−/− mice restores otoferlin expression and pre-
vents deafness. (A, Left) Confocal image of the mid-
to-apical turn of the injected cochlea from a P70
mouse, immunostained for otoferlin (green). Cell
nuclei are stained with DAPI (blue). A large pro-
portion of the IHCs, but none of the outer hair cells
(OHCs), express otoferlin. Arrowheads indicate non-
transduced IHCs. (Inset) Higher magnification of the
boxed area. (Scale bars, 50 μm and 10 μm.) (Inset). (A,
Right) Images of IHCs coimmunostained for otoferlin
(green), the ribbon protein ribeye (blue), and the
GluA2 subunit of postsynaptic glutamate receptors
(red). Synaptic active zones have a normal distribu-
tion in transduced IHCs expressing otoferlin, whereas
they tend to form clusters (arrowheads) in non-
transduced IHCs (indicated by dashed lines). (Scale
bar, 5 μm.) (B, Left) Four weeks after the dual AAV
injection, Otof−/− mice displayed ABR thresholds in
response to clicks or tone bursts at frequencies of 8
kHz, 16 kHz, and 32 kHz (green dots, n = 8) close to
those of wild-type mice (black dots, n = 8). By con-
trast, Otof−/− mice receiving AAV-Otof NT (orange
dots, n = 3) or no injection (blue dots, n = 6) had no
identifiable ABR waves up to sound intensity levels
of 86 dB SPL. (B, Right) In the Otof−/−mice treated on
P10 (arrow), the hearing thresholds for click stimuli
were stable for at least 6 mo after recovery. (C, Left)
ABR traces, recorded 3 wk after therapeutic injec-
tion, in a wild-type mouse (black), an Otof−/− mouse
(Otof−/−, blue), and a rescued Otof−/−mouse (Otof−/−
injected, green), showing similar waveforms in the
wild-type and rescued mice. (C, Right) Bar graph
showing the latency and normalized amplitude of
ABR wave I for 86 dB SPL click stimuli in rescued
Otof−/− mice (green, n = 8) and wild-type mice
(black, n = 5). Average maximum value of wave I
amplitude, measured at 86 dB SPL, was 4.6 ± 0.9 μV
and 1.8 ± 0.1 μV in Otof +/+ mice and treated Otof−/−
mice, respectively.
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mouse model, our proof of principle that cochlear delivery of a
fragmented cDNA via a dual-AAV vector approach can effec-
tively restore production of the full-length protein, resulting in a
long-lasting correction of the profound deafness phenotype of
these mice. Remarkably, this local gene therapy not only pre-
vented deafness inOtof−/−mice when administered before hearing
onset, but also reversed the deafness phenotype in a sustained
manner when administered well after hearing onset. This result
suggests that the therapeutic window for local gene transfer in
patients with congenital deafness due to DFNB9 may be longer
than initially suspected. It also opens the way for similar
preclinical studies in mouse models of other DFNB forms.
Materials and Methods
Animals. Otoferlin knockout (Otof−/−) mice produced in the C57BL/6 strain (28)
were backcrossed with FVB mice for more than 10 generations to obtain a ho-
mogeneous FVB genetic background, as this background, unlike the C57BL/6
background, is associated with stable hearing thresholds in the first 8 mo of life
(37). Recombinant AAV2 vectors were delivered to the Otof−/− mice in an FVB
genetic background. All procedures and animal handling complied with Institut
National de la Santé et de la Recherche Médicale, Institut Pasteur, and NIH
welfare guidelines, and approved protocol requirements at the University of
California, San Francisco.
Recombinant AAV2 Vector Constructs and Packaging. The full-length coding se-
quence of themurine otoferlin cDNA (Otof1 isoform1; NM_001100395.1)was divided
into a 5′ fragment (nucleotides 1–2,448) and a 3′ fragment (nucleotides 2,449–5,979),
and these fragments were synthesized (GenScript). The 5′ construct contained the 5′
part of the Otof1 cDNA (encoding amino acids 1–816, which includes the C2A, C2B,
and C2C domains of the protein) and a splice donor (SD) site, and the 3′ construct
contained the 3′ part of the Otof1 cDNA (encoding amino acids 817–1,992, which
includes the C2D, C2E, C2F, and transmembrane domains of the protein), and a splice
acceptor (SA) site. Both constructs, which contain the alkaline phosphatase recombi-
nogenic bridging sequence, were inserted into the AAV-vector plasmids as previously
described (31, 38), producing a pair of recombinant vectors referred to as AAV-Otof
NT and AAV-Otof CT. The recombinant vectors were packaged in the AAV2 quadY-F
capsid (30), and recombinant viruses were purified and titered by the University of
Florida Ocular Gene Therapy Core, as previously described (39, 40).
Transgene Expression in Transfected HEK293 Cells. HEK293 cells were grown in
six-well plates on polylysine-coated coverslips in DMEM supplemented with
Fig. 3. Dual AAV-mediated gene therapy in Otof−/−
mice on P17 durably restores otoferlin expression
and hearing. (A, Left) Confocal image of the mid-to-
apical turn of the injected cochlea from a P80 mouse,
immunostained for otoferlin (green). Cell nuclei are
stained with DAPI (blue). Most IHCs express oto-
ferlin, whereas outer hair cells (OHCs) do not.
Arrowheads indicate nontransduced IHCs. (Inset)
Higher magnification of the boxed area. (Scale bars,
50 μm and 10 μm.) (Inset). (A, Right) Images of IHCs
coimmunostained for otoferlin (green), the ribbon
protein ribeye (blue), and the GluA2 subunit of
postsynaptic glutamate receptors (red). Synaptic ac-
tive zones have a normal distribution in transduced
IHCs expressing otoferlin, whereas they tend to form
clusters (arrowheads) in nontransduced IHCs (in-
dicated by dashed lines). (Scale bar, 5 μm.) (B, Left)
ABR thresholds of untreated Otof−/− mice (blue, n =
5), treated Otof−/−mice (green, n = 5), and wild-type
mice (black, n = 5) in response to clicks or tone-burst
stimuli at frequencies of 8, 16, and 32 kHz, 4 wk after
intracochlear injection of the recombinant vector
pair in the treated mice. (B, Right) Time course of
hearing recovery in Otof−/− mice receiving injections
on P17 (arrow). Hearing restoration to near-wild-
type levels is maintained for at least 20 wk post-
injection. (C, Left) ABR traces, recorded 2 wk after
therapeutic injection, in a wild-type mouse (black),
an Otof−/− mouse (Otof−/−, blue), and a rescued
Otof−/− mouse (Otof−/− injected, green), showing
similar waveforms in the wild-type and rescued mice.
(C, Right) Bar graph showing that the latency of ABR
wave I (for 86 dB SPL click stimuli) in rescued Otof−/−
mice (n = 5) is similar to that in wild-type mice (n =
5), whereas its normalized amplitude is about half
that in wild-type mice (average maximum value of
wave I amplitude, measured at 86 dB SPL, was 4.6 ±
0.9 μV and 2.2 ± 0.4 μV in Otof +/+ mice and treated
Otof−/− mice, respectively).
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1× nonessential amino acids and 10% FBS (Gibco), and penicillin/streptomycin
(Pen/Strep; Invitrogen). On the next day, cells were infected as previously de-
scribed (41). The cells were then incubated with previously characterized rabbit
polyclonal antibodies, 14cc and C19, directed against the N-terminal part or the
C-terminal part of otoferlin (28) (dilution 1:200) at 4 °C overnight. The samples
were rinsed twice with PBS and incubatedwith Cy3-conjugated goat anti-rabbit
IgG secondary antibody (dilution 1:2,000; Life Technologies) in PBS at room
temperature for 2 h. The samples were then rinsed twice in PBS, stained with
4′,6-diamidino-2-phenylindole (DAPI) to visualize cell nuclei, mounted on a
glass slide with a drop of Fluorsave medium (Biochem Laboratories), and ob-
served with an Olympus confocal immunofluorescence microscope.
Vector Delivery to the Cochlea. The left ear was approached via a dorsal in-
cision and the virus was delivered to the cochlea as previously described (9,
42). Briefly, anesthetized Otof−/− mice received an injection of the AAV2-
Otof vector pair through the round window membrane of the cochlea on
P10, P17, or P30. A fixed volume (2 μL) containing the AAV2-Otof NT (6.3 ×
1012 vg/mL) and AAV2-Otof CT (4.5 × 1012 vg/mL) vector pair was injected.
Auditory Testing. Awake nonrescued Otof−/− mice and rescued Otof−/− mice
were tested at different time points for the presence of the Preyer’s reflex, a
rapid movement of the pinna (ear twitch) in response to narrow-band (4–
16 kHz) background noise sounds of 86 dB sound pressure level (SPL) in-
tensity. The reflex was considered positive when a rapid movement of the
pinna was clearly noticed at sound onset. Preyer’s reflex was present only in
the rescued Otof−/− mice. The mice were then anesthetized for ABR
recordings (9). ABR were recorded with the TDT BioSig III system (Tucker
Davis Technologies). The hearing threshold was defined as the lowest
stimulus level at which ABR peaks for waves I–V were clearly and re-
peatedly present upon visual inspection. These threshold evaluations were
Fig. 4. Dual AAV-mediated gene therapy in Otof−/−
mice on P30 restores otoferlin expression and hear-
ing in a sustained manner. (A, Left) Confocal image
of the mid-to-apical turn of the injected cochlea
from a P40 mouse, immunostained for otoferlin
(green). Cell nuclei are stained with DAPI (blue).
Most IHCs express otoferlin, whereas outer hair cells
(OHCs) do not. Arrowheads indicate nontransduced
IHCs. (Inset) Higher magnification of the boxed area.
(Scale bars, 50 μm and 10 μm.) (Inset). (A, Right) Im-
ages of IHCs coimmunostained for otoferlin (green),
the ribbon protein ribeye (blue), and the GluA2
subunit of postsynaptic glutamate receptors (red).
Synaptic active zones have a normal distribution in
transduced IHCs expressing otoferlin, whereas they
tend to form clusters (arrowheads) in nontransduced
IHCs (indicated by dashed lines). (Scale bar, 5 μm.) (B)
ABR thresholds of untreated Otof−/− mice (blue, n =
3), treated Otof−/−mice (green, n = 3), and wild-type
mice (black, n = 3) in response to clicks or tone-burst
stimuli at frequencies of 8, 16, and 32 kHz, 3 wk
(Left), 14 wk, and 20 wk (Right) after intracochlear
injection of the recombinant vector pair in the treated
mice. In these mice hearing restoration to near-wild-
type levels is maintained for at least 20 wk post-
injection. (C, Left) ABR traces, recorded 7 wk after
therapeutic injection, in a wild-type mouse (black),
an Otof−/−mouse (Otof−/−, blue), and a rescuedOtof−/−
mouse (Otof−/− injected, green), showing similar
waveforms in the wild-type and rescued mice. (C,
Right) Bar graph showing that the latency of ABR
wave I (for 86 dB SPL click stimuli) in rescued Otof−/−
mice (n = 3) is similar to that in wild-type mice (n =
3), whereas its normalized amplitude is about half
that in wild-type mice (average maximum value of
wave I amplitude, measured at 86 dB SPL, was 4.6 ±
0.9 μV and 2.5 ± 0.1 μV in Otof +/+ mice and treated
Otof−/− mice, respectively).
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confirmed by the offline analysis of stored waveforms. The latency of ABR
wave I was measured for sounds of high intensity (86 dB SPL) as the time
interval between the click stimulus and the peak amplitude of wave I. In
addition, the values of wave I peak amplitudes on the ABR traces were
normalized against the mean value in control wild-type mice (taken as
100%) for a comparison between rescued Otof−/− mice and wild-type mice.
Inner Hair Cell and Synaptic Ribbon Counts. Mouse cochleas were perfused
with 4% paraformaldehyde in 0.1 M PBS (pH 7.4) and incubated in the same
fixative at 4 °C for 2 h. The cochleas were rinsed three times with PBS and
decalcified by incubation with 5% ethylenediamine tetraacetic acid (EDTA) in
0.1 M PBS at 4 °C overnight. The cochlear sensory epithelium (organ of Corti)
was microdissected into a surface preparation, preincubated in 0.25% Triton X-
100 and 5% normal goat serum in PBS (blocking buffer) at room temperature
for 1 h, and incubated with the primary antibody at 4 °C overnight. The fol-
lowing antibodies were used: rabbit anti-otoferlin C-terminal part (C19, 1:250
dilution) (28), mouse (IgG1) anti-CtBP2/ribeye, mouse (IgG2a) anti-glutamate
receptor subunit A2 (1:200 dilution; Millipore), and rabbit anti-GFP (A11122;
1:250 dilution; Invitrogen). The samples were rinsed three times in PBS and
incubated with the appropriate secondary antibody: Alexa Fluor 488-conjugated
anti-mouse IgG1, Alexa Fluor 568-conjugated anti-mouse IgG2a (1:1,000 di-
lution; Life Technologies), or Atto Fluor 647-conjugated anti-rabbit IgG (1:200
dilution; Sigma). The samples were washed three times in PBS, and mounted on
a glass slide in one drop of Fluorsave, with DAPI to stain cell nuclei. Fluorescence
confocal z stacks of the organ of Corti were obtained with an LSM 700 confocal
microscope (Zeiss) equipped with a high-resolution objective (numerical aper-
ture of 1.4, 60× oil-immersion objective). Images were acquired in a 512 × 512 or
1,024 × 1,024 raster (pixel size = 0.036 μm in x and y) with 0.2-μm z steps. IHCs
producing otoferlin, and ribbon synapses defined by the presence of closely
juxtaposed CtBP2/ribeye-immunoreactive and GluA2-immunoreactive spots,
were counted using the 3D rendering of z stacks of up to 20 confocal images. To
calculate the proportion of IHCs expressing the otoferlin transgene, we divided
the total number of IHCs producing otoferlin by the total number of IHCs
identified by their DAPI-stained cell nuclei (a minimum of 150 consecutive IHCs
from the cochlear middle part were analyzed).
RT-PCR. Total mRNA was extracted (TRIzol, Invitrogen) from the left cochleas of
six Otof +/+ mice and six Otof−/−mice rescued on P10. Reverse transcription (RT)
was carried out with oligodT primers and superscript II RNase H− (Invitrogen) at
42 °C for 50 min. Two microliters of the RT reaction product were used for the
PCR (Taq DNA polymerase; Invitrogen) consisting of 35 cycles (94 °C for 30 s,
60 °C for 45 s, 72 °C for 60 s) with final extension at 72 °C for 10 min. The PCR
primer pair (forward primer TGTCTCAGAGCTCCGAGGCA and reverse primer
ATCGTGGAGGAGGAACTGGGCA) was designed to amplify a 2,676-bp in-
termediate fragment (nucleotides 27–2,702) of the otoferlin cDNA (GenBank
accession no. NM_001100395.1) encompassing the junction between the AAV-
Otof NT and AAV-Otof CT inserts. PCR products were purified by electropho-
resis on a 2% agarose gel containing 0.5 mg/mL ethidium bromide (Qiaquick
gel extraction kit), sequenced (Elim Biopharmaceuticals), and checked for se-
quence identity to the otoferlin cDNA sequence.
Statistical Analyses.Data are expressed as themean± SD. All statistical analyses
were carried out with the nonparametric Mann–Whitney U test. Statistical
significance is indicated in the figures as follows: n.s., not significant; *P < 0.05;
**P < 0.01; ***P < 0.001.
ACKNOWLEDGMENTS. We thank Dr. Victor Benichoux for critical reading of
the manuscript. This work was supported by the Hearing Research Incorporation
(O.A.), Fondation pour la Recherche Médicale (A.E.), Région Ile de France (DIM
Thérapie génique), the European Union Seventh Framework Programme under
the Grant Agreement HEALTH-F2-2010-242013 (TREAT RUSH), the French gov-
ernment funds managed by Agence Nationale de la Recherche (EargenCure),
and LabEx Lifesenses (ANR-10-BNP Paribas Foundation, FAUN Stiftung, LHW
Stiftung, and Mrs. Errera Hoechstetter).
1. Duman D, Tekin M (2012) Autosomal recessive nonsyndromic deafness genes: A re-
view. Front Biosci 17:2213–2236.
2. Kral A, O’Donoghue GM (2010) Profound deafness in childhood. N Engl J Med 363:
1438–1450.
3. Jeon EK, Turner CW, Karsten SA, Henry BA, Gantz BJ (2015) Cochlear implant users’
spectral ripple resolution. J Acoust Soc Am 138:2350–2358.
4. Vivero RJ, Fan K, Angeli S, Balkany TJ, Liu XZ (2010) Cochlear implantation in common
forms of genetic deafness. Int J Pediatr Otorhinolaryngol 74:1107–1112.
5. Flotte TR, et al. (2004) Phase I trial of intramuscular injection of a recombinant adeno-
associated virus alpha 1-antitrypsin (rAAV2-CB-hAAT) gene vector to AAT-deficient
adults. Hum Gene Ther 15:93–128.
6. Kay MA, et al. (2000) Evidence for gene transfer and expression of factor IX in hae-
mophilia B patients treated with an AAV vector. Nat Genet 24:257–261.
7. Mueller C, Flotte TR (2008) Clinical gene therapy using recombinant adeno-associated
virus vectors. Gene Ther 15:858–863.
8. Qing K, et al. (1999) Human fibroblast growth factor receptor 1 is a co-receptor for
infection by adeno-associated virus 2. Nat Med 5:71–77.
9. Akil O, et al. (2012) Restoration of hearing in the VGLUT3 knockout mouse using
virally mediated gene therapy. Neuron 75:283–293.
10. Askew C, et al. (2015) Tmc gene therapy restores auditory function in deaf mice. Sci
Transl Med 7:295ra108.
11. Chang Q, et al. (2015) Virally mediated Kcnq1 gene replacement therapy in the im-
mature scala media restores hearing in a mouse model of human Jervell and Lange-
Nielsen deafness syndrome. EMBO Mol Med 7:1077–1086.
12. Chien WW, et al. (2016) Gene therapy restores hair cell stereocilia morphology in
inner ears of deaf whirler mice. Mol Ther 24:17–25.
13. Delmaghani S, et al. (2015) Hypervulnerability to sound exposure through impaired
adaptive proliferation of peroxisomes. Cell 163:894–906.
14. Emptoz A, et al. (2017) Local gene therapy durably restores vestibular function in a
mouse model of Usher syndrome type 1G. Proc Natl Acad Sci USA 114:9695–9700.
15. Isgrig K, et al. (2017) Gene therapy restores balance and auditory functions in a mouse
model of Usher syndrome. Mol Ther 25:780–791.
16. Landegger LD, et al. (2017) A synthetic AAV vector enables safe and efficient gene
transfer to the mammalian inner ear. Nat Biotechnol 35:280–284.
17. Minoda R, Miwa T, Ise M, Takeda H (2015) Potential treatments for genetic hearing
loss in humans: Current conundrums. Gene Ther 22:603–609.
18. Pan B, et al. (2017) Gene therapy restores auditory and vestibular function in a mouse
model of Usher syndrome type 1c. Nat Biotechnol 35:264–272.
19. Dulon D, et al. (2018) Clarin-1 gene transfer rescues auditory synaptopathy in model
of Usher syndrome. J Clin Invest 128:3382–3401.
20. Song L, McGee J, Walsh EJ (2006) Frequency- and level-dependent changes in auditory
brainstem responses (ABRS) in developing mice. J Acoust Soc Am 119:2242–2257.
21. Hepper PG, Shahidullah BS (1994) Development of fetal hearing. Arch Dis Child 71:
F81–F87.
22. Choi BY, et al. (2009) Identities and frequencies of mutations of the otoferlin gene
(OTOF ) causing DFNB9 deafness in Pakistan. Clin Genet 75:237–243.
23. Rodríguez-Ballesteros M, et al. (2008) A multicenter study on the prevalence and
spectrum of mutations in the otoferlin gene (OTOF) in subjects with nonsyndromic
hearing impairment and auditory neuropathy. Hum Mutat 29:823–831.
24. Yasunaga S, et al. (1999) A mutation in OTOF, encoding otoferlin, a FER-1-like pro-
tein, causes DFNB9, a nonsyndromic form of deafness. Nat Genet 21:363–369.
25. Johnson CP, Chapman ER (2010) Otoferlin is a calcium sensor that directly regulates
SNARE-mediated membrane fusion. J Cell Biol 191:187–197.
26. Michalski N, et al. (2017) Otoferlin acts as a Ca2+ sensor for vesicle fusion and vesicle
pool replenishment at auditory hair cell ribbon synapses. eLife 6:e31013.
27. Varga R, et al. (2006) OTOF mutations revealed by genetic analysis of hearing loss
families including a potential temperature sensitive auditory neuropathy allele.
J Med Genet 43:576–581.
28. Roux I, et al. (2006) Otoferlin, defective in a human deafness form, is essential for
exocytosis at the auditory ribbon synapse. Cell 127:277–289.
29. Ghosh A, Yue Y, Duan D (2011) Efficient transgene reconstitution with hybrid dual
AAV vectors carrying the minimized bridging sequences. Hum Gene Ther 22:77–83.
30. Petrs-Silva H, et al. (2011) Novel properties of tyrosine-mutant AAV2 vectors in the
mouse retina. Mol Ther 19:293–301.
31. Dyka FM, Boye SL, Chiodo VA, Hauswirth WW, Boye SE (2014) Dual adeno-associated
virus vectors result in efficient in vitro and in vivo expression of an oversized gene,
MYO7A. Hum Gene Ther Methods 25:166–177.
32. Kros CJ, Ruppersberg JP, Rüsch A (1998) Expression of a potassium current in inner
hair cells during development of hearing in mice. Nature 394:281–284.
33. Wong AB, et al. (2014) Developmental refinement of hair cell synapses tightens the
coupling of Ca2+ influx to exocytosis. EMBO J 33:247–264.
34. Bennett J, et al. (2012) AAV2 gene therapy readministration in three adults with
congenital blindness. Sci Transl Med 4:120ra15.
35. Kumar SR, Markusic DM, Biswas M, High KA, Herzog RW (2016) Clinical development
of gene therapy: Results and lessons from recent successes. Mol Ther Methods Clin
Dev 3:16034.
36. Mingozzi F, High KA (2011) Therapeutic in vivo gene transfer for genetic disease
using AAV: Progress and challenges. Nat Rev Genet 12:341–355.
37. Kommareddi P, et al. (2015) Hair cell loss, spiral ganglion degeneration, and pro-
gressive sensorineural hearing loss in mice with targeted deletion of Slc44a2/Ctl2.
J Assoc Res Otolaryngol 16:695–712.
38. Lai Y, Yue Y, Liu M, Duan D (2006) Synthetic intron improves transduction efficiency
of trans-splicing adeno-associated viral vectors. Hum Gene Ther 17:1036–1042.
39. Zolotukhin S, et al. (2002) Production and purification of serotype 1, 2, and 5 re-
combinant adeno-associated viral vectors. Methods 28:158–167.
40. Jacobson SG, et al. (2006) Safety of recombinant adeno-associated virus type 2-RPE65
vector delivered by ocular subretinal injection. Mol Ther 13:1074–1084.
41. Lopes VS, et al. (2013) Retinal gene therapy with a large MYO7A cDNA using adeno-
associated virus. Gene Ther 20:824–833.
42. Duan M, Venail F, Spencer N, Mezzina M (2004) Treatment of peripheral sensori-
neural hearing loss: Gene therapy. Gene Ther 11(Suppl 1):S51–S56.
Akil et al. PNAS | March 5, 2019 | vol. 116 | no. 10 | 4501
M
ED
IC
A
L
SC
IE
N
CE
S
